Extended Data Fig. 5: On-chip response curves under treatment of 4-1BBζ-CAR products manufactured at 3 days or 9 days (D3-CAR and D9-CAR). | Nature Biomedical Engineering

Extended Data Fig. 5: On-chip response curves under treatment of 4-1BBζ-CAR products manufactured at 3 days or 9 days (D3-CAR and D9-CAR).

From: Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia

Extended Data Fig. 5

(a) D3-CAR (left) and D9-CAR (right) 4-1BBζ-CAR at different doses (that is, 10,000, 1,250, and 625 CAR T cells per chip). (b) Comparison between D3-CAR and D9-CAR 4-1BBζ-CAR. Data was collected from three independent experiments (n = 3), mean and s.e.m. (c) Cytokine secretion profiles of D3-CAR and D9-CAR 4-1BBζ-CAR on-chip (dose of 10,000 T cells) on day 2 were examined by using a Human Inflammation Array C3 membrane kit. Representative data of two independent experiments (n = 2). (d,e) ELISA measured secretions of granzyme B (d) and IFN-γ (e) from leukaemia chips of D3-CAR and D9-CAR treatment at different time points. Data was collected from two independent experiments (n = 2).

Source data

Back to article page